

Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy

Amy M. Inkster^{A, B}, Chaini Konwar^{A, C}, Maria S. Peñaherrera^{A, B}, Ursula Brain^A, Almas Khan^{A, E}, E. Magda Price^{A, B, F}, Johanna M. Schuetz^{A, B}, Élodie Portales-Casamar^{A, E}, Amber Burt^G, Carmen J. Marsit^G, Cathy Vaillancourt^H, Tim F. Oberlander^{A, D *}, Wendy P. Robinson^{A, B *}

A. BC Children's Hospital Research Institute (BCCHR), Vancouver, BC, V5Z 4H4, Canada.

B. Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.

C. Centre for Molecular Medicine and Therapeutics, Vancouver, BC, V6H 0B3, Canada

D. School of Population and Public Health, University of British Columbia, Vancouver, BC, V6T 1Z3, Canada.

E. Department of Pediatrics, University of British Columbia, Vancouver, BC, V6T 1Z4, Canada.

F. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, ON, K1H 5B2, Canada.

G. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, Atlanta, GA, 30322, United States of America.

H. INRS-Centre Armand Frappier and Réseau intersectoriel de recherche en santé de l'Université du Québec, Laval, QC, H7V 1B7, Canada.

*indicates co-senior authors

Address all correspondence and requests for reprints to:

Tim F. Oberlander (toberlander@bcchr.ca) or Wendy P. Robinson, PhD (wrobinson@bcchr.ca)
BC Children's Hospital Research Institute
950 W 28th Ave
Vancouver, British Columbia
V5Z 4H4, Canada

Declarations of interest: none

ABSTRACT

Background

Selective serotonin reuptake inhibitors (SSRIs) for treatment of prenatal maternal depression have been associated with neonatal neurobehavioral disturbances, though the molecular mechanisms remain poorly understood. *In utero* exposure to SSRIs may affect DNA methylation (DNAm) in the human placenta, an epigenetic mark that is established during development and is associated with gene expression.

Methods

Chorionic villus samples from 64 human placentas were profiled with the Illumina MethylationEPIC BeadChip; clinical assessments of maternal mood and SSRI treatment records were collected at multiple time points during pregnancy. Case distribution was 20 SSRI-exposed cases and 44 SSRI non-exposed cases. Maternal depression was defined using a mean maternal Hamilton Depression score >8 to indicate symptomatic depressed mood (“maternally-depressed”), and we further classified cases into SSRI-exposed, maternally-depressed (n=14); SSRI-exposed, not maternally-depressed (n=6); SSRI non-exposed, maternally-depressed (n=20); and SSRI non-exposed, not maternally-depressed (n=24). For replication, Illumina 450K DNAm profiles were obtained from 34 additional cases from an independent cohort (n=17 SSRI-exposed, n=17 SSRI non-exposed).

Results

No CpGs were differentially methylated at $FDR < 0.05$ comparing SSRI-exposed to non-exposed placentas, in a model adjusted for mean maternal Hamilton Depression score, or in a model

restricted to maternally-depressed cases with and without SSRI exposure. However, at a relaxed threshold of $FDR < 0.25$, five CpGs were differentially methylated ($|\Delta\beta| > 0.03$) by SSRI exposure status. Four were covered by the replication cohort measured by the 450K array, but none replicated. No CpGs were differentially methylated ($FDR < 0.25$) comparing maternally depressed to not depressed cases. In sex-stratified analyses for SSRI-exposed versus non-exposed cases (females $n=31$; males $n=33$), three additional CpGs in females, but none in males, were differentially methylated at the relaxed $FDR < 0.25$ cut-off.

Conclusions

We did not observe large-scale alterations of DNAm in placentas exposed to maternal SSRI treatment compared to placentas with no SSRI exposure. We also found no evidence for altered DNAm in maternal depression-exposed versus depression non-exposed placentas. This novel work in a prospectively-recruited cohort with clinician-ascertained SSRI exposure and mood assessments would benefit from future replication.

KEYWORDS

Placenta, SSRI, depression, pregnancy, antidepressant, DNA methylation, Illumina EPIC array, sex differences

BACKGROUND

As many as 20% of pregnant individuals suffer from mood disorders such as depression during pregnancy, and up to 6% of all pregnant individuals are treated with antidepressants such as

selective serotonin reuptake inhibitors (SSRIs), based on estimates from several North American and European studies (1–4). Clinical management decisions for treatment of perinatal depression are complex, and in each case the clinician must balance the risks of treatment with the severity of depressive symptoms (5). Given the prevalence of maternal depression and SSRI treatment during gestation, much research has been conducted focusing on the fetal effects of both (6,7).

Maternal prenatal depressed mood has been associated with preterm birth (< 37 weeks of gestation), growth and developmental delays, and increased postnatal infant stress (8,9). Additionally, the literature suggests that the presence of maternal depressive symptoms independent of SSRI therapy is associated with increases in offspring childhood internalizing behaviours and affective disorders, though these exposures are hard to separate in human studies (10). Animal studies have permitted further investigation into the effect of maternal depressed mood on offspring outcomes by enabling the randomization of SSRI treatment. Rodent models have confirmed that associations identified between maternal depressed mood and offspring anxiety disorders are not mediated by SSRI exposure, and that SSRI treatment does not protect offspring from these outcomes; this topic is reviewed in (10).

Regarding the impacts of SSRI treatment on the feto-placental unit, Oberlander *et al.* previously found that maternal SSRI treatment was associated with altered blood flow to the fetus, increased rates of fetal hypoxemia, altered early neurodevelopment, lower arousal index throughout the newborn period, and altered psychomotor test scores (6,7,11–13). Prenatal SSRI exposure also tended to be associated with lower fetal-placental weight ratios and poorer fetal vascular perfusion, indicative of less efficient fetal blood flow to or from the placenta (14). Both of these

factors indicate less efficient placental function in association with prenatal SSRI exposure, which may be related to downstream neonatal cognitive outcomes (14). Exposure to maternal SSRI treatment has previously been reported to affect syncytialization of placental trophoblasts and extravillous trophoblast function, and to affect placental serotonin levels (15–17). Taken together, the effect of SSRI exposure on pregnancy outcomes suggests an interplay between the placenta and SSRI pharmacobiology, which could occur by a variety of mechanisms. It has, however, been postulated that both depression and SSRI exposure may impact fetal outcomes via altered serotonin signalling and downstream effects.

Serotonin (5-hydroxytryptamine, or 5-HT) is a central neurotransmitter and a critical signaling factor in many contexts, including during prenatal neurodevelopment of the fetus (18). Low levels of serotonin in the central nervous system have historically been associated with depressive symptoms in adults, in the 5-HT theory of depression (19). SSRI therapeutics, which increase extracellular levels of 5-HT, have been associated with alleviation of depressive symptoms (20). *In vivo*, serotonin is synthesized from the essential amino acid L-tryptophan, by tryptophan hydroxylase enzymes 1 and 2 (TPH-1, TPH-2), and is degraded by monoamine oxidases A and B (MAOA, MAOB) (21,22). SSRIs function to block the serotonin transporter (SERT, also known as 5-HTT (5-hydroxytryptamine transporter)), inhibiting the reabsorption of 5-HT by the presynaptic neurons and thereby increasing extracellular serotonin levels in the central nervous system (13). Several aspects of serotonin and SSRI biology are relevant to prenatal development, and both maternal depression and SSRI exposure have been associated with altered fetal outcomes. Notably, serotonin is first expressed early in gestation, when placental TPH-1 and TPH-2 convert maternal L-tryptophan to serotonin *de novo* (22,23). Over

the course of gestation, serotonin (5-HT) is essential to many processes of prenatal development including embryogenesis, placentation, and neurodevelopment (21,24,25). SSRIs readily cross the placenta, leading to fetal drug exposure and altered fetal cardiac autonomic activity, presumably via altered serotonin signaling in the placenta and/or fetus (26,27).

One plausible mechanism by which SSRI exposure may impact pregnancy outcomes is via DNA methylation (DNAm). DNAm is an epigenetic mark involving the addition of a methyl group to the 5' carbon of a cytosine molecule, which usually occurs in the context of cytosine-guanine dinucleotides (CpGs). In human tissues, DNAm signatures are associated with gene expression patterns (28), and are altered in association with certain environmental and chemical exposures, such as air pollution, arsenic, and tobacco smoke; for a review of this topic see (29).

DNAm patterns in the human placenta vary in association with certain maternal exposures and environments, but are relatively stable once established and serve as a possible record of gene expression patterns and exposures in gestation (30,31). The placenta exists at the interface of the maternal environment and the developing fetus, and environmental factors can gain access to the fetus in many cases only via the placenta (32,33). As SSRIs readily cross the placenta (34), it is possible that SSRI species alter placental DNAm patterns directly via association with epigenetic readers and writers (DNMT or TET enzymes), or through altering gene expression patterns in the serotonin signalling pathway, or other related pathways (29).

In this study, we hypothesized that prenatal SSRI treatment would be associated with distinct placental DNAm signatures. In a prospective cohort of 64 placentas with extensive maternal

mood assessments during gestation, both with and without SSRI exposure, we investigated the effects of maternal SSRI treatment and maternal depressed mood on placental DNA methylation profiles. We considered the effect of SSRI exposure on placental DNAm as our primary outcome. The secondary outcome considered was the impact of maternal depression, which was investigated among participants not treated with SSRIs. Additionally, given previously reported sex differences in neurodevelopmental and placental outcomes related to maternal stress (35–40), we also assessed placental DNAm associated with maternal SSRI treatment in separate sex-stratified models.

METHODS

Discovery cohort

Participants were recruited as part of a prospective, longitudinal cohort approved by the University of British Columbia/Children’s and Women’s Health Centre of British Columbia research ethics board: H12-00733 (40). Written informed consent was obtained from all participants, and all procedures complied with the ethical standards on human experimentation and with the Helsinki Declaration of 1975 (revised in 2008). This specific study was additionally approved under certificate H16-02280.

Pregnant individuals with and without prenatal diagnoses of clinical depression, and with/without SSRI treatment plans were recruited at the British Columbia Women’s Hospital (BCWH) in the 20th week of gestation (n=64). At recruitment, all pregnant individuals received the MINI assessment to screen for DSM-IV Axis I Depression. SSRI use was reported by the

treating clinicians, and was defined as treatment for at least 75 days including the 3rd trimester with one of the following: fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), escitalopram (Lexapro), or venlafaxine (Effexor). Compliance with SSRI treatment was assessed and recorded at each prenatal study visit. While placental drug concentrations were not available at the time of this study, previous work on this cohort indicated that maternal plasma drug concentrations during gestation were consistent with self-report of SSRI use (26). Maternal mood was assessed at recruitment, 36 weeks of gestation, postnatal day 6, and at 24 months postnatally. The mood assessment included multiple clinician and patient-rated measures, of which the Hamilton Depression score, a 17-item clinician implemented assessment of the severity of depressive symptoms (41), and the Edinburgh Postnatal Depression score (EPDS), a 10-item self-assessment screening tool for depression (42), were analyzed.

Exclusion criteria were: bipolar illnesses, hypertension, any diabetes, current substance abuse, placental insufficiency, multi-fetal pregnancies, infants with congenital brain malformations, intrauterine growth restriction, or preterm birth. For all participants, measures of obstetric history, prenatal medication use, and sociodemographic variables were obtained. At birth, additional clinical information was collected for each infant including gestational age at delivery, infant sex assigned at birth, and infant birth weight; placentas were collected for DNAm studies.

After delivery, chorionic villus samples were obtained from 4 distinct cotyledonary sites (1.5-2 cm³) below the surface of the fetal-facing side of each placenta, as previously described (43). DNA was extracted from each of the 4 sites and pooled in equimolar amounts to provide a representative sample of the whole placenta prior to obtaining DNAm profiles. DNAm data for

these 64 cases was collected in a single processing batch using the Illumina MethylationEPIC (“EPIC”) array platform (Illumina, San Diego, CA, USA), which profiles >850,000 CpGs genome-wide.

Case distribution was as follows: 20 SSRI-exposed and 44 SSRI non-exposed samples (Table 1). Cases were additionally sub-categorized into four groups for analysis based on both SSRI exposure and maternal depression status using a mean maternal Hamilton Depression score of >8 to indicate symptomatic depressed mood (“maternally depressed”) as follows: SSRI-exposed, maternally-depressed (n=14); SSRI-exposed without maternal depression (n=6); SSRI non-exposed, maternally depressed (n=20); and SSRI non-exposed without maternal depression (n=24), see Table 2 and Figure 1.

Replication cohort

An independent cohort of 34 cases with (i) known SSRI-exposure status and (ii) pre-collected placental DNAm data were obtained from a subset of the Rhode Island Child Healthy Study (RICHS) (44). Cohort participants were treated with one of the following SSRIs: fluoxetine, paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), or escitalopram (Lexapro). Assessments of maternal mood were not available for these cases. DNAm data for these 34 cases were previously collected with the Illumina HumanMethylation450 (“450K”) array platform, and are available on the Gene Expression Omnibus (GEO) repository under accession number GSE75248 (44).

223 *Table 1. Demographics of the discovery and replication cohorts by SSRI exposure status. SSRI*
 224 *refers to selective-serotonin reuptake inhibitor treatment during pregnancy. Birthweight Z-*
 225 *scores were calculated using gestational-age and sex-adjusted birthweight curves (45).*

Discovery Cohort			
	SSRI-exposed	Non-SSRI-exposed	<i>p</i> value†
n	20	44	
Maternal Hamilton Depression Score (mean (SD))			
26 weeks	10.6 (5.4)	6.6 (3.6)	0.001**
36 weeks	10.8 (4.2)	8.3 (3.6)	0.021*
Mean	10.6 (4.5)	7.5 (3.5)	0.004**
Length SSRI exposure (days, mean (SD))	264.4 (29.9)	-	-
Type of SSRI exposure (n (%)) □			
Citalopram	7 (35.0)	-	-
Escitalopram	7 (35.0)	-	
Fluoxetine	1 (5.0)	-	
Paroxetine	1 (5.0)	-	
Sertraline	4 (20.0)	-	
Delivery type (n vaginal (%))	10 (50.0)	29 (65.9)	0.351
Gestational age at birth (weeks, mean (SD))	39.3 (1.4)	39.6 (1.3)	0.438
Gestational diabetes (n, mean (SD))	0 (0)	0 (0)	-
Infant sex (n male (%))	8 (40.0%)	25 (56.8%)	0.328
Infant birthweight Z-score (mean (SD))	-0.01 (1.00)	-0.03 (0.73)	0.915
PlaNET Ancestry[§] (mean (SD))			
Coordinate 1	0.00 (0.00)	0.00 (0.01)	0.354
Coordinate 2	0.05 (0.21)	0.13 (0.31)	0.300
Coordinate 3	0.95 (0.21)	0.86 (0.31)	0.286
Replication Cohort			
	SSRI-exposed	Non-SSRI-exposed	<i>p</i> value†
n	17	17	
Type of SSRI exposure (n (%)) □			
Citalopram	3 (17.6)	-	-

Escitalopram	2 (11.8)	-	
Fluoxetine	2 (11.8)	-	
Paroxetine	1 (5.9)	-	
Sertraline	9 (52.9)	-	
Delivery type (n vaginal (%))	4 (23.5)	12 (70.6)	0.016*
Gestational age at birth (weeks, mean (SD))	39.0 (0.9)	39.0 (0.9)	0.999
Infant sex (n male (%))	7 (41.2)	10 (58.8)	0.493
Gestational diabetes (n mean (SD))	5 (29.4)	3 (18.8)	0.758
PlaNET Ancestry[§]			
Coordinate 1	0.00 (0.01)	0.08 (0.25)	0.212
Coordinate 2	0.01 (0.04)	0.12 (0.32)	0.174
Coordinate 3	0.98 (0.05)	0.80 (0.38)	0.057

226 †p values are from chi-squared tests for categorical variables and t-tests for continuous variables,

227 comparing SSRI-exposed to SSRI non-exposed, * indicates <0.05, ** indicates <0.005.

228 §The PlaNET algorithm outputs DNAME-based ancestry probability values ranging from 0-1,

229 which sum to 1 for each sample. Coordinate 1 is associated with probability of African ancestry,

230 coordinate 2 with East Asian ancestry, and coordinate 3 with European ancestry (46).

231 *Table 2. Discovery cohort demographics by SSRI and depression group status. Maternal depression was categorized using mean*
 232 *maternal Hamilton Depression score, ≤ 8 was categorized as not depressed, > 8 as depressed, this is reflected in the “Depression*
 233 *Group” row. SSRI refers to selective-serotonin reuptake inhibitor treatment during pregnancy. Birthweight Z scores were calculated*
 234 *using gestational-age and sex-adjusted birthweight curves (45).*

	SSRI-exposed, maternally- depressed	SSRI-exposed, not maternally depressed	SSRI non- exposed, maternally- depressed	SSRI non- exposed, not maternally- depressed	SSRI exposed vs non-exposed <i>p</i> value [†] (maternally- depressed)	SSRI exposed vs non-exposed <i>p</i> value [†] (not maternally- depressed)
Depression Group	Depressed	Not depressed	Depressed	Not Depressed	Depressed vs. Depressed	Not Depressed vs. Not Depressed
n	14	6	20	24		
Maternal Hamilton Depression Score (mean (SD))						
26 weeks	13.4 (3.9)	4.5 (2.4)	9.7 (2.6)	4.3 (2.2)	0.003*	0.841
36 weeks	12.8 (2.8)	5.6 (2.6)	11.0 (2.2)	5.8 (2.7)	0.045*	0.869
Mean	13.0 (2.9)	5.2 (1.8)	10.5 (2.2)	5.0 (2.1)	0.009*	0.877
Length SSRI exposure (days, mean (SD))	266.93 (19.28)	258.33 (48.65)	-	-	-	-
Type of SSRI exposure (n (%))[‡]						
Citalopram	5 (35.7)	2 (33.3)	-	-	-	-
Escitalopram	5 (35.7)	2 (33.3)	-	-		

Fluoxetine	0 (0.0)	1 (16.7)	-	-		
Paroxetine	1 (7.1)	0 (0.0)	-	-		
Sertraline	3 (21.4)	1 (16.7)	-	-		
Delivery type (n vaginal (%))	5 (35.7)	5 (83.3)	11 (55.0)	18 (75.0)	0.281	0.99
Gestational age at birth (weeks, mean (SD))	39.1 (1.4)	39.7 (1.4)	39.6 (1.3)	39.5 (1.4)	0.447	0.697
Gestational diabetes (n, mean (SD))	0 (0)	0 (0)	0 (0)	0 (0)	-	-
Infant sex (n male (%))	6 (42.9%)	2 (33.3%)	11 (55.0%)	14 (58.3%)	0.727	0.522
Infant birthweight Z-score (mean (SD))	-0.01 (1.06)	0.00 (0.94)	-0.02 (0.62)	-0.05 (0.82)	0.989	0.906
PlaNET Ancestry[§] (mean (SD))						
Coordinate 1	0.00 (0.00)	0.00 (0.00)	0.01 (0.02)	0.00 (0.00)	0.292	0.665
Coordinate 2	0.07 (0.25)	0.01 (0.01)	0.14 (0.32)	0.12 (0.31)	0.488	0.370
Coordinate 3	0.93 (0.25)	0.99 (0.01)	0.85 (0.32)	0.87 (0.31)	0.460	0.369

†p values are from chi-squared tests for categorical variables and t-tests for continuous variables, * indicates <0.05, ** indicates <0.005.

□ p = 0.59 (chi-squared test) for proportion of SSRI types utilized by SSRI-exposed, maternally-depressed participants versus SSRI-exposed, not maternally-depressed participants.

239 [§]The PlaNET algorithm outputs DName-based ancestry probability values ranging from 0-1, which sum to 1 for each sample.
240 Coordinate 1 is associated with probability of African ancestry, coordinate 2 with East Asian ancestry, and coordinate 3 with
241 European ancestry (46).
242

Data processing

Processing and normalization of the Illumina EPIC DNAm data for the discovery cohort is described in full in the Supplementary Methods. First, sample sex (XY chromosome complement) and genetic uniqueness were assessed and confirmed to match the annotated metadata. Next, polymorphic and cross-hybridizing probes were removed from this dataset (47), as were probes with a detection p value > 0.01 in $> 5\%$ of cases. Subsequently, CpGs with non-variable DNAm in this cohort ($n=87,572$) were removed from the dataset to decrease multiple test correction burden. Non-variable CpGs were defined as in (48) as CpGs that met both of the following conditions: (i) $< 5\%$ range in DNAm beta (β) values between the 10th-90th centile, and (ii) previously reported as placenta-non-variable in (49). After processing and dasen + noob normalization (50), 659,036 autosomal CpGs in 64 cases plus 8 pairs of technical replicates remained for analysis. The technical replicates were used to estimate an absolute delta beta ($|\Delta\beta|$) cut-off for subsequent analyses, based on the average root mean squared error of the technical replicate pairs (0.026) and the average standard error of all CpGs in all cases (0.0048). The highest of these values was selected and rounded up, to establish a $|\Delta\beta|$ cut-off of > 0.03 between groups; anything less than $|\Delta\beta| = 0.03$ could represent technical noise and was unlikely to be biologically meaningful in this cohort. After processing, the replicate pairs were removed from the cohort and excluded from downstream analysis.

Batch correction was performed after identifying an effect of EPIC array row on DNAm data using Principal Components Analysis, see Supplementary Figure S1. Prior to batch correction, the distribution of cases across EPIC array rows was confirmed to be independent of our primary outcomes of interest: SSRI status (Fisher test $p > 0.05$) and mean maternal Hamilton depression

score (ANOVA $p > 0.05$), see Supplementary Figure S2. ComBat was used to correct the remaining categorical effect of the “row” variable, with SSRI exposure (yes/no) and mean maternal Hamilton Depression score (continuous) included as variables of interest in the ComBat model matrix as recommended by the *sva* package authors (51). Results for batch-corrected analyses were confirmed in non-batch-corrected data to ensure that false signal was not introduced during batch correction, in accordance with the recommendations outlined in (52), see Supplementary Figure S1.

Replication cohort

The raw data for the full 335-sample RICHs cohort was downloaded from GEO (GSE75248) and processed analogously to the discovery cohort: first sample sex and genetic uniqueness were checked, data were *dasen* + *noob* normalized, and polymorphic and cross-hybridizing probes were removed (47), as were probes with a detection p value > 0.01 in $> 5\%$ of cases. For a complete description of data processing see the Supplementary Methods. The processed data were subsetted to 34 cases for which gestational SSRI treatment status was recorded in the medical chart. Replication cohort demographics are presented in Table 1.

Covariate selection

We next sought to identify characteristics that could be associated with SSRI exposure in the discovery and replication cohorts, and that should be included as covariates in statistical models. Demographic variables considered include those presented in Table 1 and Table 2. The discovery cohort was well-balanced across all demographic variables by both SSRI exposure and maternal depression status. Gestational age, infant sex, and PlaNET ancestry were selected for inclusion as

additive covariates in linear modelling analyses as it is known that these factors drive large amounts of DNAm variation in the placenta (46,53). The same variables were selected in the replication cohort (infant sex, gestational age at birth, PlaNET ancestry), with the addition of type of delivery (vaginal/other), as delivery type frequency differed by SSRI exposure in the replication cohort only, see Table 1.

Using tools from the *PlaNET* R package (54,55), we also estimated additional variables in the discovery cohort from the DNAm data itself: the proportion of six major placental cell types (cytotrophoblasts, syncytiotrophoblasts, endothelial cells, stromal cells, Hofbauer cells, and nucleated red blood cells), and placental epigenetic age. Cell type proportions were not significantly associated with either SSRI treatment or mean maternal Hamilton Depression score across gestation (t-test for cell type proportions ~ SSRI exposed (yes/no), all p values > 0.05 ; Pearson correlation for mean maternal Hamilton Depression score and each cell type proportion, all p values > 0.05), see Supplementary Figure S3. Accordingly, cell type proportions were not included as covariates in subsequent linear models. Epigenetic age acceleration was calculated as the residual of the Control Placental Clock epigenetic age regressed on gestational age at birth, adjusted for sex, ancestry, and EPIC array row. Intrinsic epigenetic age acceleration (cell-type independent) was calculated similarly, but with additional adjustment for numeric cell type proportions. Placental epigenetic age was not considered as a possible covariate in linear models, but was analyzed separately for associations with SSRI exposure, as previous cord blood studies have reported conflicting relationships between cord blood epigenetic age acceleration and SSRI treatment, so parallel exploration in the placenta was warranted (56,57), see Results.

Linear modelling to identify placental DNAm associated with SSRI exposure and maternal depression

To identify differential DNAm associated with both SSRI exposure and exposure to maternal depression in the discovery cohort, three linear models were explored, see Figure 1. Linear modelling on M values was conducted using *limma* in R (58,59). In addition to the main effects, all models were adjusted for infant sex, gestational age at birth (in weeks), EPIC array row, and two of three PlaNET ancestry coordinates (46); EPIC array row was included as a covariate according to the recommended implementation of ComBat per the *sva* package authors (51). In (A) the SSRI model, the full cohort was used for a linear model to assess the effect of SSRI exposure ($n_{\text{exposed}} = 20$ versus $n_{\text{non-exposed}} = 44$) on placental DNAm, adjusting for mean maternal Hamilton Depression score across gestation. In (B) the SSRIs in maternal depression model, we used only cases with maternal depression (mean maternal Hamilton Depression score > 8 , $n=34$) and assessed the effect of SSRI exposure in exposed ($n=14$) versus SSRI non-exposed cases ($n=20$). In (C) the maternal depression without SSRIs model, we used only cases without SSRI exposure during gestation ($n=44$), and assessed the effect of maternal depression alone by comparing SSRI non-exposed, maternally-depressed cases ($n=20$) to not maternally-depressed cases ($n=24$). Multiple test correction for all models was performed using the Benjamini-Hochberg false discovery rate method (60).

For replication analyses, linear models were run only on the CpGs of interest (M values), identified in the discovery cohort models A-C. Replication linear models were adjusted for infant sex, gestational age at birth, two of three PlaNET ancestry coordinates, and type of delivery

(vaginal/other). CpGs were considered to replicate differential DNAm in association with SSRI exposure at a nominal p value < 0.05 in the replication cohort.




Figure 1. Comparisons for analysis of differential DNAm associated with SSRI exposure and maternal depression in the discovery cohort. (A) The SSRI model investigates SSRI exposure in the full cohort (n=64), comparing SSRI-exposed (n=20) to SSRI non-exposed (n=44) cases, adjusting for mean maternal Hamilton Depression score across gestation. (B) The SSRIs in maternal depression model investigates SSRI exposure in all maternally-depressed cases (mean maternal Hamilton Depression score >8, n=34), this model compares SSRI-exposed, maternally depressed cases (n=14) to SSRI non-exposed, maternally depressed cases (n=20). (C) The maternal depression without SSRIs model investigates the effect of maternal depression in cases not exposed to SSRIs (n=44), this model compares SSRI non-exposed, maternally depressed cases (n=20) to SSRI non-exposed and not maternally depressed cases (n=24).

RESULTS

SSRI exposure and maternal depression are not associated with widespread alterations in placental DNAm patterns

First, we assessed in separate models whether DNAm was altered in placentas with SSRI exposure or exposure to maternal depression during gestation. No CpGs were significantly differentially methylated at the commonly used statistical threshold of FDR < 0.05 in any of the three models tested. Plotting FDR against the $|\Delta\beta|$ for all CpG sites tested in the three models demonstrated very few DNAm associations with either SSRI exposure or maternal depression array-wide, see Figure 2.




Figure 2. Volcano plots for differential DNAm in association with SSRI exposure and categorical depression. For all plots HamD refers to the mean maternal Hamilton Depression score across gestation for each individual. False discovery rate (FDR) is shown along the Y axis with more significant (lower FDR) values at the top of the plot. Vertical dashed intercepts demarcate $|\Delta\beta| = 0.03$, horizontal dashed intercepts indicate from top to bottom FDR = 0.05, FDR = 0.15, and FDR = 0.25 (A) Volcano plot for the SSRI model, investigating differential DNAm associated with SSRI exposure adjusted for mean maternal HamD score, (n=64). Difference in DNAm ($\Delta\beta$) is plotted along the X axis and was calculated as $\Delta\beta = \beta_{\text{SSRI-exposed}} -$

$\beta_{\text{SSRI non-exposed}}$. **(B)** Volcano plot for the SSRIs in maternal depression model, differential

DNAme associated with SSRI exposure in cases with mean maternal HamD score > 8 , (n=34).

Difference in DNAme ($\Delta\beta$) is plotted along the X axis and was calculated as $\Delta\beta = \beta_{\text{SSRI-exposed}} -$

$\beta_{\text{SSRI non-exposed}}$. **(C)** Volcano plot for the maternal depression without SSRIs model, differential

DNAme associated HamD score > 8 across gestation, in SSRI non-exposed cases, (n=44).

Difference in DNAme ($\Delta\beta$) is plotted along the X axis and was calculated as $\Delta\beta = \beta_{\text{Hamilton} > 8} -$

$\beta_{\text{Hamilton} \leq 8}$.

Since the relatively small sample size of the discovery cohort could limit our ability to detect

significant between-group DNAme differences, in addition to the standard threshold of $\text{FDR} <$

0.05, we also evaluated CpGs that met more relaxed thresholds of $\text{FDR} < 0.15$ and $\text{FDR} < 0.25$.

As these thresholds are associated with increased expected proportions of false positive findings,

we have labelled $\text{FDR} < 0.15$ hits “moderate-confidence” and $\text{FDR} < 0.25$ “low-confidence”. For

both $\text{FDR} < 0.15$ and $\text{FDR} < 0.25$ thresholds, we maintained a minimum effect size threshold of

$|\Delta\beta| > 0.03$.

At these relaxed thresholds, in the SSRI model (model A) adjusted for mean maternal Hamilton

Depression score, one CpG was differentially methylated at $\text{FDR} < 0.15$, and one more at $\text{FDR} <$

0.25, see Figure 2 and Supplementary Table S1. The one differentially methylated CpG at $\text{FDR} <$

0.15 (cg12900404) exhibited a $\Delta\beta$ of +0.11 (higher average DNAme β value in SSRI-exposed

placentas). Loosening the threshold to $\text{FDR} < 0.25$, one additional CpG was differentially

methylated by SSRI exposure status (cg20877313), and was also more highly methylated in

SSRI-exposed placentas ($\Delta\beta=+0.04$). In the SSRIs in maternal depression model (model B),

three CpGs were differentially methylated at the moderate-confidence threshold of $FDR < 0.15$ (cg12655501, cg26993610, cg14340829). These CpGs all had an average difference in DNAm between SSRI-exposed and SSRI non-exposed cases of $|\Delta\beta| > 0.10$. In the maternal depression without SSRIs model (model C), no CpGs showed evidence of maternal depression-associated differential DNAm at any FDR threshold. For a description of all CpGs that satisfied the moderate and low-confidence FDR thresholds from the SSRI models (A, B) and SSRIs in maternal depression model (C), including test statistics and overlapping genes, see Table 3. Summary statistics of linear modelling from all CpGs tested are presented in Supplementary Tables S2-S4. Boxplots showing average DNAm β values in SSRI-exposed versus SSRI non-exposed cases for the differentially methylated CpGs are shown in Figure 3.

A differentially methylated region (DMR) analysis was also conducted, to increase power for discovering DNAm-associations by grouping signatures from multiple neighboring CpG sites to reduce the number of statistical comparisons. DMR analysis was only conducted for the SSRI model to enable utilization of the entire cohort of cases and maximize statistical power.

M values were assessed for being part of DMRs for which average DNAm differed by SSRI exposure status using the *DMRcate* R package ($FDR < 0.25$, $\lambda = 1000$, $C = 2$) (61). Only one DMR was identified with an average DNAm β value that differed by SSRI exposure, this DMR comprised of two CpGs 70 base pairs apart (cg06762403 and cg14921691) on chromosome 12, overlapping the *DGKA* gene. The average $\Delta\beta$ across the region was +0.06, indicating higher DNAm in SSRI-exposed placentas, see Table 3 and Supplementary Figure S4.

414 **Table 3. Top CpGs with differential DName by SSRI-exposure status. Linear modelling p**
 415 **value and false discovery rates (FDR) shown, $\Delta\beta$ is difference in DName calculated as $\Delta\beta =$**
 416 **$\beta_{SSRI-exposed} - \beta_{SSRI non-exposed}$. hg19 chromosome (Chr) and coordinates (Position) for each CpG are**
 417 **indicated, as are genes that each CpG overlaps, and whether each CpG is covered by a probe on**
 418 **the 450K DNA methylation array. A and B in the Model Column refer to model A and model B,**
 419 **DMR refers to the differentially-methylated region analysis.**

Model	CpG	p value	FDR	FDR threshold	$\Delta\beta$	Chr:Position	Gene Symbol	Relation to Gene	450K locus?
A	cg12900404	9.11e-08	0.06	Moderate confidence	0.11	2:225811669	DOCK10	1 st Exon	-
A	cg20877313	6.05e-07	0.20	Low confidence	0.04	12:56881753	GLS2	1 st Exon	Yes
B	cg12655501	6.07e-07	0.14	Low confidence	-0.12	1: 115603524	TSPAN2	Body	-
B	cg26993610	6.26e-07	0.14	Low confidence	0.14	1:115605466	TSPAN2	Body	-
B	cg14340829	1.80e-07	0.12	Low confidence	-0.10	8:923973	-	-	Yes
DMR	cg14921691, cg06762403	-	1.95e-29	-	0.06	12: 56325797-56325867	DGKA	5'UTR, 1 st Exon	Yes

420




Figure 3. Boxplots of differentially methylated CpGs by SSRI exposure. For all plots, points are colored by SSRI exposure (blue = SSRI non-exposed, dark yellow = SSRI-exposed), and boxplots indicate mean DNAm β value \pm one standard deviation. (A) Boxplot of cg12900404, identified in the SSRI model, model A. (B) Boxplot of cg20877313, identified in the SSRI model, model A. (C) Boxplot of cg12655501, identified in the SSRIs in maternal depression model, model B. (D) Boxplot of cg26993610, identified in the SSRIs in maternal depression model, model B. (E) Boxplot of cg14340829, identified in the SSRIs in maternal depression model, model B.

Few placental DNAm differences associated with SSRI exposure in sex-stratified models

As the effects of SSRI exposure might differ by sex, we next sought to assess whether unique SSRI-exposure DNAm associations arose in placentas of male versus female infants. Sex-stratified linear models were run in males (n=33, 24% SSRI-exposed) and females (n=31, 39% SSRI-exposed) to test for SSRI-exposure associated DNAm, adjusting for mean maternal Hamilton Depression Score, gestational age at birth, EPIC array row, and PlaNET ancestry. At an FDR < 0.25 and $|\Delta\beta| > 0.03$, no CpGs were differentially methylated by SSRI exposure in males. In females, at an FDR < 0.25 and $|\Delta\beta| > 0.03$, three CpGs (cg15849349, cg07481545, and cg03905236) were differentially methylated in association with SSRI exposure (Supplementary Figure S5).

We previously identified 162 CpGs with robust sex differences in placental DNAm patterns that replicated in an independent dataset (62). To investigate sex in another context, we tested whether these previously-ascertained sex-differentially-methylated CpGs were also differentially methylated by SSRI exposure status. All 162 replicated CpGs were considered, and were subjected to linear modelling in the discovery cohort for SSRI exposure, adjusting for mean maternal Hamilton Depression Score, gestational age at birth, EPIC array row, and PlaNET ancestry. No CpGs met significance at FDR < 0.05. At the low-confidence FDR < 0.25 threshold, three CpGs (cg22515303, cg27003571, cg26136722) had lower DNAm in SSRI-exposed placentas than non-exposed placentas, in addition to the previously identified sex effect at these loci (Supplementary Figure S6).

No replication of DNAm signature associated with SSRI exposure in an independent dataset

We next intended to assess the reproducibility of the five CpGs with SSRI-associated differential DNAm identified in the SSRI model and SSRIs in maternal depression model (Table 3), and the two DMR CpGs. As the replication cohort was run on the Illumina 450K array, only four of these seven discovery cohort CpGs could be assessed for replication (cg14340829, cg20877313, cg06762403, cg14921691). A linear model was applied to the M values from these four CpGs in the replication cohort to test for differential DNAm associated with SSRI exposure, adjusting for infant sex, gestational age at birth, mode of delivery, and PlaNET ancestry. None of the four CpGs replicated differential methylation at a nominal p value < 0.05 in the replication dataset, see Supplementary Figure S7.

Placental epigenetic age acceleration not associated with SSRI exposure or maternal depression

Epigenetic age is a useful dimension-reduction technique to analyze relationships between global DNAm patterns and a variety of health outcomes. Altered epigenetic age relative to chronological age (“epigenetic age acceleration”) has been associated with several negative health outcomes including overall greater burden of disease and higher rates of all-cause mortality (63,64). Specific to depression, major depressive disorder is associated with increased epigenetic age acceleration in adult blood (65). Umbilical cord blood epigenetic age deceleration was initially reported in maternal depression (56), but interestingly this association has since been demonstrated to be largely related to the confounding signature of maternal SSRI treatment rather than depression itself (57).

Using a recently published placental epigenetic clock (55), we calculated epigenetic age acceleration in the discovery cohort. We then tested for associations between epigenetic age acceleration metrics and either SSRI exposure or mean maternal Hamilton Depression score using linear models. Neither epigenetic age acceleration nor intrinsic epigenetic age acceleration (cell-type independent) were significantly associated with either SSRI exposure or maternal depression, see Supplementary Figure S8.

Replication of previously reported differential methylation candidates associated with SSRI-exposure and maternal depression in the discovery cohort

A previous study identified 16 CpGs with altered placental DNAm associated with maternal depression (treated as a categorical variable, where depression was maternal EPDS > 10) at FDR < 0.05 (no $|\Delta\beta|$ threshold) (66). EPDS measurements were also collected for the discovery cohort cases in our study, and were significantly collinear with mean maternal Hamilton Depression scores across gestation, see Supplementary Figure S9. To assess whether these previously-reported CpGs were also differentially methylated in association with maternal EPDS in the discovery cohort, we ran a linear model on the DNAm M values from these 16 CpGs, adjusting for infant sex, gestational age at birth, ancestry, and EPIC array row. One CpG (cg06670742) satisfied a nominal p value < 0.05 in our cohort, and had higher DNAm in cases with higher mean maternal EPDS scores (FDR < 0.05, $\Delta\beta=+0.003$). Thus, differential DNAm of this CpG did replicate in our study, however the effect size in our cohort was very small and does not exceed the technical threshold we set of $|\Delta\beta| > 0.03$ (Figure 4).

499 Three previous studies investigated genome-wide DNAm alterations associated with SSRI
500 treatment in a prenatal tissue (cord blood). An early study by Non et al. (2014) found no
501 association between SSRI exposure and cord blood DNAm at any CpG loci (67). Cardenas *et*
502 *al.* (2019) reported one differentially methylated CpG in the gene body of *ZNF575* associated
503 with maternal antidepressant treatment in a cohort of cord blood samples (68). In a different
504 cohort, Kallak et al. (2021) reported 13 CpGs differentially methylated by SSRI exposure status
505 in cord blood (69). Though cord blood DNAm is very distinct from placenta, we sought to
506 evaluate whether any of the 14 CpGs reported by Cardenas et al. (68) or Kallak et al. (69) were
507 also differentially methylated by SSRI exposure status in the placenta. At the CpG reported by
508 Cardenas et al. (cg22159528) we found no difference in DNAm by SSRI exposure (nominal p
509 value > 0.05), see Figure 4. At one of the 13 CpGs reported by Kallak et al., we found nominally
510 significant ($p < 0.05$) differential DNAm associated with SSRI exposure status in the placenta
511 in the same direction as the original cord blood association: higher DNAm in SSRI-exposed
512 cases. This was cg00331486 in LOC284930 on chromosome 22, which encodes a MYC-
513 interacting long noncoding RNA species (69).




Figure 4. Assessment of literature candidates for SSRI and depression-associated DNAm in the discovery cohort. (A) Scatterplot showing the association between DNAm and maternal Edinburgh Postnatal Depression Score (EPS) at cg06670742 which was previously found to be differentially methylated in association with maternal EPDS score in Tesfaye et al. (2021) (37) and is differentially methylated by SSRI exposure at FDR < 0.05 in our discovery cohort. DNAm β value at this CpG is plotted along the Y axis, mean maternal EPDS score is plotted along the X axis and each point is a case; $\Delta\beta$ per unit increase in EPDS is $\Delta\beta=+0.003$. (B) Boxplot showing mean DNAm β value \pm one standard deviation by SSRI exposure status at cg22159628 in ZNF575, previously found to be differentially methylated in cord blood with

antidepressant exposure. Linear modelling p value = 0.67, points are colored by SSRI exposure (blue = SSRI non-exposed, dark yellow = SSRI-exposed), n.s. = not significant. (C) Boxplot showing mean DNAm β value \pm one standard deviation by SSRI exposure status at cg00331486 in LOC284930 on chromosome 22, previously found to be differentially methylated in cord blood by SSRI exposure status.

DISCUSSION

In this study, we examined genome-wide placental DNAm patterns associated with SSRI exposure or maternal depression during gestation. Taken together, our results suggest the absence of a major impact of SSRI antidepressant exposure on the placental DNA methylome. Specifically, we found no differentially methylated CpGs associated with either SSRI exposure or maternal depression that met the standard significance threshold of $FDR < 0.05$. These results hold despite known alterations elicited by SSRIs to maternal gestational serotonin signalling and infant outcomes, suggesting that the effects of SSRI exposure on infant outcomes are not associated with a coincident DNAm signature in the placenta.

At more relaxed statistical thresholds, differential DNAm analysis highlighted five CpGs associated with SSRI exposure status. Three of the five differentially methylated CpGs overlapped the following genes, respectively: *DOCK10* (CpG not present in replication cohort), *GLS2* (CpG did not replicate), and *TSPAN2* (CpG not present in replication cohort). The *DOCK10* gene encodes the Dopamine Receptor Interacting Protein (70), and was recently found to be one of the twelve most predictive mRNA biomarkers of depression in a gene expression study of adult whole blood (71). These researchers identified that *DOCK10* expression was

higher in association with a more positive, less depressed mood (71). *DOCK10* is also a target of increased expression by the action of the antidepressant ketamine(71). *TSPAN2* encodes Tetraspanin-2, which mediates signal transduction in processes related to cellular growth and development (72). *Tspan2* has been reported to be upregulated in the rat hippocampus after chronic exposure to the SSRI fluoxetine (73). We also identified one differentially methylated region in the 5' untranslated region of *DGKA*, with higher DNAm in SSRI exposed placentas. *DGKA* encodes a diacylglycerol kinase that is involved in intracellular signalling (74), and *DGKA* activity was recently reported to be inhibited by Ritanserin, a pharmaceutical serotonin receptor type 2 (5-HT₂) antagonist that is not currently in clinical use (75).

Inherent to studying the impact of SSRI exposure are the concurrent, and potentially confounding, effects of maternal mood disturbances. As such, studies must be carefully designed to interrogate the effects of either SSRI treatment or depression exposure while accounting for the other factor. Only a limited placental DNAm signature has so far been associated with maternal mood disorders (66), and no work has been conducted to our knowledge interrogating genome-wide placental DNAm signatures associated with SSRI exposure. Tesfaye *et al.* (66) investigated placental DNAm in association with maternal depression, though SSRI treatment or antidepressant use was not reported on or investigated and could underlie some of these associations. Of the 16 CpGs they identified as differentially methylated by maternal depression status across six gestational time points, only one CpG in the *EPS15L1* gene was also differentially methylated our study by mean maternal EPDS score across gestation (FDR < 0.05), and although the effect was in the same direction, the effect size ($\Delta\beta = +0.003$ with each unit

increase in mean EPDS) was well below our biological $|\Delta\beta|$ threshold of > 0.03 , and therefore may not be a biologically meaningful change in DNAm.

In non-placental tissue, Kallak et al. (69) identified 13 CpGs that were differentially methylated in cord blood in association with SSRI exposure, one of which replicated at nominal significance in the same direction (higher DNAm in SSRI-exposed cases) in our cohort. Cardenas et al. also identified one CpG in the gene body of *ZNF575* (cg22159528) with lower DNAm in antidepressant-exposed cord blood samples from Project Viva, which they replicated in an external cohort (Generation R Study) (68). In our cohort, placental DNAm at this CpG was not associated with SSRI exposure. Although cord blood and placenta are both conceptus-derived tissues relevant to prenatal development and early life, they have unique origins (embryonic versus extraembryonic lineages, respectively) and thus distinct DNAm profiles are expected. Our finding that cord blood differential DNAm does not replicate at high rates in the placenta may suggest a cord-blood-specific DNAm signature at these CpGs in association with maternal SSRI treatment.

In sex-stratified analyses, three CpGs were differentially methylated by SSRI exposure in females: two in intergenic regions on chromosomes 4 and 6 respectively, and one in the 5' untranslated region of the *SH3GL3* gene. *SH3GL3* encodes the Endophilin-A3 protein, which interacts selectively with the Huntingtin protein to promote the formation of polyglutamine-containing protein aggregates (76). Promoter DNA methylation of the *SH3GL3* gene was previously inversely correlated with its expression in human colon cancer cell lines versus matched double knockout cell lines for DNMT1 and DNMT3b (77). Lower DNAm upstream of

the promoter of the *SH3GL3* gene in SSRI-exposed female placentas may indicate higher expression of this gene relative to the placentas from SSRI non-exposed females, which should be followed up in future work. In a second sex-focused analysis we tested whether previously reported sex-biased CpGs (62) were differentially methylated by SSRI status, three CpGs met the low-confidence FDR < 0.25 threshold (two in the 5' untranslated region of *GTDC1*, one in the gene body of *C14orf132*). Together, these analyses suggest that there may be a sex-biased signature of SSRI treatment on the placental DNA methylome or transcriptome, and future studies in this field should be designed to analyze sex as a variable of interest.

The major strength of our study lies in the curation of both SSRI treatment and maternal depression information per participant. This prospective design enabled us to investigate the potential confounding effects of these two variables in controlled contexts (i.e. studying SSRI exposure while adjusting for depression scores, and studying the effect of maternal depression in SSRI non-exposed samples). Additionally, in this study we measured genome-wide DNAm in an effort to reduce bias that arises from candidate gene or CpG pyrosequencing studies, and utilized the most modern Illumina EPIC array platform to capture the highest resolution data currently afforded by a DNAm microarray. Further strengths of our study include strict effect size and significance thresholds, the presence of an external replication cohort, the ability to account for covariates such as genetic ancestry and cell type proportions, and the ability to stratify analyses by sex.

Limitations of this work include SSRI exposure being defined as maternal treatment with any of six different SSRIs during gestation. It is possible that the SSRI subtypes have different effects

on placental DNAm, though this study was not able to undertake sub analysis by SSRI type, and future work should consider this. The extent to which SSRI treatment improves maternal depression scores (i.e. remittance of symptoms) may also be associated with placental DNAm patterns and should be investigated in future longitudinal cohorts. Lastly, although sample size was relatively small, our cohort is among one of a handful of prospectively recruited cohorts that we are aware of with placental tissue collected alongside maternal depression and SSRI treatment information, including the BASIC and Generation R Studies (78,79). Cord blood DNAm data exists for both of these cohorts and has previously been studied in association with maternal SSRI exposure (68,69). Cohorts such as these, with extensive clinical records of maternal mood and medication use across gestation are incredibly valuable resources to investigate how depression status and antidepressant medications may interact with fetal outcomes.

In conclusion, our work demonstrates that limited placental DNAm alterations are associated with maternal SSRI exposure; this work agrees with earlier findings of a similarly limited placental DNAm signature of maternal depression. Future work in larger cohorts will determine whether other molecular alterations may co-exist with maternal mood disorders or SSRI treatment, such as altered placental gene expression patterns. As larger cohorts with clinical characterization of maternal SSRI treatment and prenatal depressed mood become available, genetic sequence variation, gene expression patterns, and DNA methylation alterations should all be considered, as well as their interactions.

DECLARATIONS

Data availability statement

The raw and preprocessed EPIC array data and corresponding sample metadata supporting the conclusions of this article are available on the Gene Expression Omnibus (GEO), under the accession number [GSE203396](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE203396).

Ethics approval and consent to participate

Participants were recruited as part of a prospective, longitudinal cohort approved by the University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (UBC C&W REB) (H12-00733 (40)), this sub study was also approved by the same ethics boards (H16-02280).

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by a grant from the National Institutes of Health (1R01HD089713-01). Collection of the Discovery Cohort was funded by a Canadian Institutes of Health Research grant (MOP-5783). WPR receives salary support through an investigatorship award from the BC Children's Hospital Research Institute. AMI is funded by a Frederick Banting and Charles Best Canada Doctoral Scholarship from the Canadian Institutes of Health Research.

Authors' contributions

AMI conducted the analyses and wrote the manuscript, and contributed to sample processing, quality control, and testing. CK conducted a preliminary analysis of the effect of SSRI exposure on an earlier version of this data, and contributed to sample processing, quality control, and testing. MSP is the NIH project manager, curated and organized clinical data, contributed to sample processing, quality control, and testing, and manuscript editing. UB conducted clinical data collection. AK processed and normalized the discovery cohort EPIC array data. EMP and JMS were involved in data management, sample metadata collation and establishment of the RedCap database, and participated in randomization. ÉPC oversaw project administration and data curation of this cohort. AB performed data curation for the RICHS cohort cases, CJM is cohort owner of the RICHS data and organized data curation for this set of cases. CV contributed to the conceptualization and design of this project, and also contributed to funding acquisition. TFO and WPR were responsible for project administration, funding acquisition, and supervision of the SSRI cohort recruitment and the DNAME data generation aims of the project, respectively, and were major contributors in writing and revising the manuscript. TO designed the original study. AMI, CK, MSP, UB, AK, EMP, JMS, ÉPC, CV, TFO, and WPR all participated in experimental design. All authors read, revised, and approved the final version of the manuscript.

Acknowledgements

We acknowledge all cohort owners and collaborators on the “Using ‘omics to build an atlas of placental development and function across pregnancy” (NIH Project). Thank you to Dr. Michael S. Kobor and the BCCHRI Microarray Core Facilities for support with Illumina EPIC DNAME runs. We thank Robinson lab members Ruby Jiang, Giulia F. Del Gobbo, and Desmond Hui for their work in sample processing, quality control, and testing, thank you to Victor Yuan and Ziqi

Liu for pilot data processing for cases from this cohort. Finally, we sincerely thank the pregnant individuals and families that contributed placental samples to this study.

REFERENCES

1. Andersson L, Sundström-Poromaa I, Bixo M, Wulff M, Bondestam K, Åström M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. *Am J Obstet Gynecol*. 2003 Jul;189(1):148–54.
2. Gorman LL, O'Hara MW, Figueiredo B, Hayes S, Jacquemain F, Kammerer MH, et al. Adaptation of the structured clinical interview for DSM-IV disorders for assessing depression in women during pregnancy and post-partum across countries and cultures. *Br J Psychiatry Suppl*. 2004 Feb;46:s17–23.
3. Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ. Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. *Obstet Gynecol*. 2010 Nov;116(5):1064–70.
4. Tran H, Robb AS. SSRI use during pregnancy. *Semin Perinatol*. 2015 Nov 1;39(7):545–7.
5. Kim DR, O'Reardon JP, Epperson CN. Guidelines for the Management of Depression During Pregnancy. *Curr Psychiatry Rep*. 2010 Aug;12(4):279–81.
6. Hanley GE, Oberlander TF. The effect of perinatal exposures on the infant: Antidepressants and depression. *Best Pract Res Clin Obstet Gynaecol*. 2014 Jan 1;28(1):37–48.
7. Hanley GE, Brain U, Oberlander TF. Prenatal exposure to serotonin reuptake inhibitor antidepressants and childhood behavior. *Pediatr Res*. 2015 Aug;78(2):174–80.
8. Goodman SH, Halperin MS. Perinatal depression as an early stress: Risk for the development of psychopathology in children. In: *The Oxford handbook of stress and mental health*. New York, NY, US: Oxford University Press; 2020. p. 287–312. (Oxford library of psychology).
9. Talge NM, Neal C, Glover V, Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? *J Child Psychol Psychiatry*. 2007 Apr;48(3–4):245–61.
10. Hutchison SM, Mâsse LC, Pawluski JL, Oberlander TF. Perinatal selective serotonin reuptake inhibitor (SSRI) and other antidepressant exposure effects on anxiety and depressive behaviors in offspring: A review of findings in humans and rodent models. *Reprod Toxicol Elmsford N*. 2021 Jan;99:80–95.
11. Oberlander T, Gingrich J, Ansorge M. Sustained Neurobehavioral Effects of Exposure to SSRI Antidepressants During Development: Molecular to Clinical Evidence. *Clin Pharmacol Ther*. 2009 Dec;86(6):672–7.

12. Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander TF. Third Trimester Fetal Heart Rate and Doppler Middle Cerebral Artery Blood Flow Velocity Characteristics During Prenatal Selective Serotonin Reuptake Inhibitor Exposure. *Pediatr Res*. 2011 Jul;70(1):96–101.
13. Rotem-Kohavi N, Oberlander TF. Variations in Neurodevelopmental Outcomes in Children with Prenatal SSRI Antidepressant Exposure. *Birth Defects Res*. 2017;109(12):909–23.
14. Levy M, Kovo M, Miremberg H, Anchel N, Herman HG, Bar J, et al. Maternal use of selective serotonin reuptake inhibitors (SSRI) during pregnancy—neonatal outcomes in correlation with placental histopathology. *J Perinatol*. 2020 Jul;40(7):1017–24.
15. Clabault H, Flipo D, Guibourdenche J, Fournier T, Sanderson JT, Vaillancourt C. Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. *Toxicol Appl Pharmacol*. 2018 Jun 15;349:8–20.
16. Clabault H, Cohen M, Vaillancourt C, Sanderson JT. Effects of selective serotonin-reuptake inhibitors (SSRIs) in JEG-3 and HIPEC cell models of the extravillous trophoblast. *Placenta*. 2018 Dec;72–73:62–73.
17. Thibeault AAH, de Los Santos YL, Doucet N, Sanderson JT, Vaillancourt C. Serotonin and serotonin reuptake inhibitors alter placental aromatase. *J Steroid Biochem Mol Biol*. 2019 Dec;195:105470.
18. Velasquez J, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects of SSRIs and maternal depression. *Front Cell Neurosci*. 2013;7:47.
19. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. *Philos Trans R Soc B Biol Sci*. 2012 Sep 5;367(1601):2378–81.
20. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin theory of depression: a systematic umbrella review of the evidence. *Mol Psychiatry*. 2022 Jul 20;1–14.
21. St-Pierre J, Laurent L, King S, Vaillancourt C. Effects of prenatal maternal stress on serotonin and fetal development. *Placenta*. 2016 Dec;48 Suppl 1:S66–71.
22. Bonnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, et al. A transient placental source of serotonin for the fetal forebrain. *Nature*. 2011;472(7343):347–50.
23. Laurent L, Deroy K, St-Pierre J, Côté F, Sanderson JT, Vaillancourt C. Human placenta expresses both peripheral and neuronal isoform of tryptophan hydroxylase. *Biochimie*. 2017 Sep 1;140:159–65.
24. Karahoda R, Abad C, Horackova H, Kastner P, Zaugg J, Cerveny L, et al. Dynamics of Tryptophan Metabolic Pathways in Human Placenta and Placental-Derived Cells: Effect of Gestation Age and Trophoblast Differentiation. *Front Cell Dev Biol*. 2020 Sep 18;8:574034.

- 751 25. Karahoda R, Robles M, Marushka J, Stranik J, Abad C, Horackova H, et al. Prenatal inflammation as
752 a link between placental expression signature of tryptophan metabolism and preterm birth. *Hum*
753 *Mol Genet*. 2021 Jun 24;30(22):2053–67.
- 754 26. Campbell KSJ, Collier AC, Irvine MA, Brain U, Rurak DW, Oberlander TF, et al. Maternal Serotonin
755 Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late
756 Gestation. *Front Psychiatry*. 2021 Aug 16;12:680177.
- 757 27. Laurent L, Huang C, Ernest SR, Berard A, Vaillancourt C, Hales BF. In utero exposure to venlafaxine,
758 a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental
759 and heart serotonin signaling in the rat. *Birt Defects Res A Clin Mol Teratol*. 2016
760 Dec;106(12):1044–55.
- 761 28. Dhar GA, Saha S, Mitra P, Nag Chaudhuri R. DNA methylation and regulation of gene expression:
762 Guardian of our health. *The Nucleus*. 2021 Dec 1;64(3):259–70.
- 763 29. Martin EM, Fry RC. Environmental Influences on the Epigenome: Exposure- Associated DNA
764 Methylation in Human Populations. *Annu Rev Public Health*. 2018 Apr 1;39:309–33.
- 765 30. Chatterjee S, Ouidir M, Tekola-Ayele F. Genetic and in utero environmental contributions to DNA
766 methylation variation in placenta. *Hum Mol Genet*. 2021 Nov 1;30(21):1968–76.
- 767 31. Vlahos A, Mansell T, Saffery R, Novakovic B. Human placental methylome in the interplay of
768 adverse placental health, environmental exposure, and pregnancy outcome. *PLOS Genet*. 2019
769 Aug 1;15(8):e1008236.
- 770 32. Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. *Philos Trans R Soc B Biol Sci*.
771 2015 Mar 5;370(1663):20140066.
- 772 33. Pemathilaka RL, Reynolds DE, Hashemi NN. Drug transport across the human placenta: review of
773 placenta-on-a-chip and previous approaches. *Interface Focus*. 2019 Oct 6;9(5):20190031.
- 774 34. Ewing G, Tatarchuk Y, Appleby D, Kim D. Placental Transfer of Antidepressant Medications:
775 Implications for Postnatal Adaptation Syndrome. *Clin Pharmacokinet*. 2015 Apr;54(4):359–70.
- 776 35. Clifton VL. Review: Sex and the Human Placenta: Mediating Differential Strategies of Fetal Growth
777 and Survival. *Placenta*. 2010 Mar 1;31:S33–9.
- 778 36. Bale TL. Sex differences in prenatal epigenetic programming of stress pathways. *Stress*. 2011 Jul
779 1;14(4):348–56.
- 780 37. Bale TL. The placenta and neurodevelopment: sex differences in prenatal vulnerability. *Dialogues*
781 *Clin Neurosci*. 2016 Dec;18(4):459–64.
- 782 38. Gobinath AR, Workman JL, Chow C, Lieblich SE, Galea LAM. Sex-dependent effects of maternal
783 corticosterone and SSRI treatment on hippocampal neurogenesis across development. *Biol Sex*
784 *Differ*. 2017 Jun 2;8:20.

39. Sutherland S, Brunwasser SM. Sex Differences in Vulnerability to Prenatal Stress: a Review of the Recent Literature. *Curr Psychiatry Rep* [Internet]. 2018 Nov [cited 2018 Oct 5];20(11). Available from: <http://link.springer.com/10.1007/s11920-018-0961-4>
40. Campbell KSJ, Williams LJ, Bjornson BH, Weik E, Brain U, Grunau RE, et al. Prenatal antidepressant exposure and sex differences in neonatal corpus callosum microstructure. *Dev Psychobiol*. 2021 Sep;63(6):e22125.
41. Rohan KJ, Rough JN, Evans M, Ho SY, Meyerhoff J, Roberts LM, et al. A Protocol for the Hamilton Rating Scale for Depression: Item Scoring Rules, Rater Training, and Outcome Accuracy with Data on its Application in a Clinical Trial. *J Affect Disord*. 2016 Aug;200:111–8.
42. Murray D, Cox JL. Screening for depression during pregnancy with the edinburgh depression scale (EDDS). *J Reprod Infant Psychol*. 1990 Apr 1;8(2):99–107.
43. Blair JD, Yuen RKC, Lim BK, McFadden DE, von Dadelszen P, Robinson WP. Widespread DNA hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia. *Mol Hum Reprod*. 2013 Oct;19(10):697–708.
44. Paquette AG, Houseman EA, Green BB, Lesueur C, Armstrong DA, Lester B, et al. Regions of variable DNA methylation in human placenta associated with newborn neurobehavior. *Epigenetics*. 2016 Jul 1;11(8):603–13.
45. Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved population-based Canadian reference for birth weight for gestational age. *Pediatrics*. 2001 Aug;108(2):E35.
46. Yuan V, Price EM, Del Gobbo G, Mostafavi S, Cox B, Binder AM, et al. Accurate ethnicity prediction from placental DNA methylation data. *Epigenetics Chromatin*. 2019 Aug 9;12(1):51.
47. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. *Nucleic Acids Res*. 2017 Feb 28;45(4):e22.
48. Edgar RD, Jones MJ, Robinson WP, Kobor MS. An empirically driven data reduction method on the human 450K methylation array to remove tissue specific non-variable CpGs. *Clin Epigenetics*. 2017 Feb 2;9(1):11.
49. Dieckmann L, Cruceanu C, Lahti-Pulkkinen M, Lahti J, Kvist T, Laivuori H, et al. Reference-Based Versus Reference-Free Cell Type Estimation In DNA Methylation Studies Using Human Placental Tissue [Internet]. In Review; 2021 Sep [cited 2021 Dec 13]. Available from: <https://www.researchsquare.com/article/rs-848651/v1>
50. Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. *BMC Genomics*. 2013 May 1;14:293.
51. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics*. 2012 Mar 15;28(6):882–3.

- 821 52. Nygaard V, Rødland EA, Hovig E. Methods that remove batch effects while retaining group
822 differences may lead to exaggerated confidence in downstream analyses. *Biostatistics*. 2016 Jan
823 1;17(1):29–39.
- 824 53. Konwar C, Del Gobbo G, Yuan V, Robinson WP. Considerations when processing and interpreting
825 genomics data of the placenta. *Placenta*. 2019 Sep;84:57–62.
- 826 54. Yuan V, Hui D, Yin Y, Peñaherrera MS, Beristain AG, Robinson WP. Cell-specific characterization of
827 the placental methylome. *BMC Genomics*. 2021 Jan 6;22(1):6.
- 828 55. Lee Y, Choufani S, Weksberg R, Wilson SL, Yuan V, Burt A, et al. Placental epigenetic clocks:
829 estimating gestational age using placental DNA methylation levels. *Aging*. 2019 Jun
830 24;11(12):4238–53.
- 831 56. Suarez A, Lahti J, Czamara D, Lahti-Pulkkinen M, Knight AK, Girchenko P, et al. The Epigenetic Clock
832 at Birth: Associations With Maternal Antenatal Depression and Child Psychiatric Problems. *J Am
833 Acad Child Adolesc Psychiatry*. 2018 May;57(5):321–328.e2.
- 834 57. McKenna BG, Hendrix CL, Brennan PA, Smith AK, Stowe ZN, Newport DJ, et al. Maternal prenatal
835 depression and epigenetic age deceleration: testing potentially confounding effects of prenatal
836 stress and SSRI use. *Epigenetics*. 2021 Mar;16(3):327–37.
- 837 58. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression
838 analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015 Apr 20;43(7):e47–
839 e47.
- 840 59. Bass A, Robinson D, Lianoglou S, Nelson E, Storey J, Gatto W. biobroom: Turn Bioconductor objects
841 into tidy data frames. [Internet]. Available from: <https://github.com/StoreyLab/biobroom>
- 842 60. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
843 to Multiple Testing. *J R Stat Soc Ser B Methodol*. 1995;57(1):289–300.
- 844 61. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, Lord RV, et al. De novo identification of
845 differentially methylated regions in the human genome. 2015;16.
- 846 62. Inkster AM, Yuan V, Konwar C, Matthews AM, Brown CJ, Robinson WP. A cross-cohort analysis of
847 autosomal DNA methylation sex differences in the term placenta. *Biol Sex Differ*. 2021 May
848 27;12(1):38.
- 849 63. Gale CR, Marioni RE, Harris SE, Starr JM, Deary IJ. DNA methylation and the epigenetic clock in
850 relation to physical frailty in older people: the Lothian Birth Cohort 1936. *Clin Epigenetics*. 2018
851 03;10(1):101.
- 852 64. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol*. 2013;14(10):R115.
- 853 65. Han LKM, Aghajani M, Clark SL, Chan RF, Hattab MW, Shabalin AA, et al. Epigenetic Aging in Major
854 Depressive Disorder. *Am J Psychiatry*. 2018 Aug 1;175(8):774–82.

- 855 66. Tesfaye M, Chatterjee S, Zeng X, Joseph P, Tekola-Ayele F. Impact of depression and stress on
856 placental DNA methylation in ethnically diverse pregnant women. *Epigenomics*. 2021
857 Sep;13(18):1485–96.
- 858 67. Non AL, Binder AM, Kubzansky LD, Michels KB. Genome-wide DNA methylation in neonates
859 exposed to maternal depression, anxiety, or SSRI medication during pregnancy. *Epigenetics*. 2014
860 Jul;9(7):964–72.
- 861 68. Cardenas A, Faleschini S, Cortes Hidalgo A, Rifas-Shiman SL, Baccarelli AA, DeMeo DL, et al.
862 Prenatal maternal antidepressants, anxiety, and depression and offspring DNA methylation:
863 epigenome-wide associations at birth and persistence into early childhood. *Clin Epigenetics*. 2019
864 Mar 29;11(1):56.
- 865 69. Kallak TK, Bränn E, Fransson E, Johansson Å, Lager S, Comasco E, et al. DNA methylation in cord
866 blood in association with prenatal depressive symptoms. *Clin Epigenetics*. 2021 Dec;13(1):1–14.
- 867 70. DOCK10 [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for
868 Biotechnology Information; 2004 – [cited 2022 Mar 25]. Available from:
869 <https://www.ncbi.nlm.nih.gov/gene/55619>.
- 870 71. Le-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, et al. Precision medicine for
871 mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs.
872 *Mol Psychiatry*. 2021 Jul;26(7):2776–804.
- 873 72. TSPAN2 [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for
874 Biotechnology Information; 2004 – [cited 2022 Mar 25]. Available from:
875 <https://www.ncbi.nlm.nih.gov/gene/10100>.
- 876 73. Kroeze Y, Peeters D, Boule F, van den Hove DLA, van Bokhoven H, Zhou H, et al. Long-term
877 consequences of chronic fluoxetine exposure on the expression of myelination-related genes in
878 the rat hippocampus. *Transl Psychiatry*. 2015 Sep;5(9):e642–e642.
- 879 74. DGKA [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for
880 Biotechnology Information; 2004 – [cited 2022 Mar 25]. Available from:
881 <https://www.ncbi.nlm.nih.gov/gene/1606>.
- 882 75. Boroda S, Niccum M, Raje V, Purow BW, Harris TE. Dual activities of ritanserin and R59022 as DGKα
883 inhibitors and serotonin receptor antagonists. *Biochem Pharmacol*. 2017 Jan 1;123:29–39.
- 884 76. Sittler A, Wälter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, et al. SH3GL3 associates
885 with the Huntingtin exon 1 protein and promotes the formation of polyGln-containing protein
886 aggregates. *Mol Cell*. 1998 Oct;2(4):427–36.
- 887 77. Kang JY, Song SH, Yun J, Jeon MS, Cha Y, Lee SH, et al. Identification of Long-Range Epigenetic
888 Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. *Am J Pathol*. 2015
889 Mar 1;185(3):666–78.

- 890 78. Axfors C, Bränn E, Henriksson HE, Hellgren C, Kunovac Kallak T, Fransson E, et al. Cohort profile:
891 the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a
892 population-based Swedish cohort. *BMJ Open*. 2019 Oct 22;9(10):e031514.
- 893 79. Jaddoe VWV, Mackenbach JP, Moll HA, Steegers EAP, Tiemeier H, Verhulst FC, et al. The
894 Generation R Study: Design and cohort profile. *Eur J Epidemiol*. 2006;21(6):475–84.
- 895

A

SSRI Model

To assess the effect of **SSRI Exposure** in all cases,
adjusting for **mean maternal Hamilton Depression score**

Group	SSRI-exposed (20)		SSRI non-exposed (44)	
	Maternally-depressed	Not maternally-depressed	Maternally-depressed	Not maternally-depressed
n	14	6	20	24

B

SSRIs in Maternal Depression Model

To assess the effect of **SSRI Exposure**
in maternally-depressed cases


C

Maternal Depression without SSRIs Model


To assess the effect of **Maternal Depression**
in SSRI non-exposed cases

A.


Model A
SSRI Model
SSRI Exposure (adjusted for mean HamD)






**B.**


Model B
SSRIs in Maternal Depression
SSRI Exposed versus Non-Exposed

**C.**


Model C
Maternal Depression without SSRIs
Depressed (HamD > 8 Yes vs No)





A.*EPSt5L1*cg06670742 nominal $p < 0.05$ **B.***ZNF575*

cg22159528 n.s.

**C.***LOC284930*cg00331486 nominal $p < 0.05$ 